Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Benjamin Musher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4997-1751; OpenAlex author ID A5050671493. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 1)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 trial · 2019: 2 papers · 2020: 1 trial · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. Co-author DOI 10.1038/s41591-025-04043-5↗
  2. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): resul… Co-author DOI 10.1016/s1470-2045(24)00079-2↗
  3. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  4. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable … Co-author DOI 10.1097/sla.0000000000004669↗
  5. Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer. Last author DOI 10.1007/s12029-017-0033-8↗
  6. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  7. Oncolytic viral therapy for pancreatic cancer. First author DOI 10.1002/jso.24626↗
  8. Pancreatic cancer disparities in African Americans. Co-author DOI 10.1097/mpa.0000000000000323↗

Trials 2

  1. Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma Principal investigator NCT04157127↗
  2. TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer Principal investigator NCT03192462↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ann Marie Leen · 2 shared papers, 2024–2026 · strength 0.39
  2. Brandon George Smaglo · 2 shared papers, 2024–2026 · strength 0.39
  3. George Van Buren · 2 shared papers, 2015–2026 · strength 0.28
  4. Anne Leen · 1 shared trial, 2018 · strength 0.26
  5. Helen E Heslop · 1 shared paper, 2026 · strength 0.22
  6. Cliona M. Rooney · 1 shared paper, 2026 · strength 0.22
  7. Zev A. Wainberg · 2 shared papers, 2019–2023 · strength 0.21
  8. Noelle K. LoConte · 2 shared papers, 2019–2022 · strength 0.19
  9. Angelica Loskog · 1 shared paper, 2024 · strength 0.16
  10. Eric Keith Rowinsky · 1 shared paper, 2024 · strength 0.16
  11. Emma Eriksson · 1 shared paper, 2024 · strength 0.16
  12. Gustav Jörgen Ullenhag · 1 shared paper, 2024 · strength 0.16
  13. Linda C. Sandin · 1 shared paper, 2024 · strength 0.16
  14. Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
  15. Ahmad Khalil Rahal · 1 shared paper, 2017 · strength 0.15
  16. Davendra P. S. Sohal · 1 shared paper, 2023 · strength 0.14
  17. Vivek U. Nimgaonkar · 1 shared paper, 2023 · strength 0.14
  18. Arnav Mehta · 1 shared paper, 2023 · strength 0.14
  19. Andrew Eugene Hendifar · 1 shared paper, 2023 · strength 0.14
  20. Pranav Rajpurkar · 1 shared paper, 2023 · strength 0.14
  21. Eric Andrew Collisson · 1 shared paper, 2023 · strength 0.14
  22. Shalini Makawita · 1 shared paper, 2023 · strength 0.14
  23. Julia Sidenius Johansen · 1 shared paper, 2023 · strength 0.14
  24. Christos K Fountzilas · 1 shared paper, 2023 · strength 0.14
  25. Aatur Dilip Singhi · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.